keyword
MENU ▼
Read by QxMD icon Read
search

Paritaprevir

keyword
https://www.readbyqxmd.com/read/29447085/paritaprevir-ritonavir-ombitasvir-plus-dasabuvir-in-hiv-hcv-coinfected-patients-with-genotype-1-in-real-life-practice
#1
Juan A Pineda, Antonio Rivero-Juárez, Ignacio de Los Santos, Antonio Collado, Dolores Merino, Luis E Morano-Amado, María J Ríos, Montserrat Pérez-Pérez, Francisco Téllez, Rosario Palacios, Ana B Pérez, María Mancebo, Antonio Rivero, Juan Macías
Background Data on the efficacy, safety, and concomitant use with other drugs of the combination ritonavir-boosted paritaprevir/ombitasvir plus dasabuvir (PrOD) in HIV/HCV-coinfected patients in real life are limited. The objectives of this study were to analyze these topics in HIV/HCV-coinfected subjects bearing HCV genotype 1 (GT1). Methods One hundred and eighty-two HIV/HCV-coinfected patients with GT1 (87 1a, 71 1b, 23 other) treated with PrOD, plus ribavirin (RBV) in 119 cases, in routine clinical practice were analyzed...
February 15, 2018: HIV Clinical Trials
https://www.readbyqxmd.com/read/29435907/sustained-virological-response-in-special-populations-with-chronic-hepatitis-c-using-interferon-free-treatments-a-systematic-review-and-meta-analysis-of-observational-cohort-studies
#2
REVIEW
Vinicius Lins Ferreira, Letícia Paula Leonart, Fernanda Stumpf Tonin, Helena Hiemisch Lobo Borba, Roberto Pontarolo
BACKGROUND AND OBJECTIVES: Hepatitis C treatment has changed considerably in recent years, and many interferon (IFN)-free therapies are now available. Considering the high rates of sustained virological response (SVR) presented by clinical trials for these treatments, high rates of effectiveness are also expected in real-world clinical practice. Hence, this study aimed to conduct a systematic review and meta-analysis of observational cohort studies to evaluate the clinical effectiveness and safety of IFN-free therapies for hepatitis C...
February 12, 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29430226/a-hepatitis-c-virus-associated-chronic-hepatitis-patient-developing-various-adverse-events-including-severe-gingivitis-gingival-bleeding-and-inflammation-of-genital-vulva-during-the-course-of-antiviral-therapy-with-elbasvir-grazoprevir
#3
Kazuo Tarao, Akira Sato
Oral direct-acting antivirals comprise the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the primary agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. Ombitasvir/paritaprevir/ritonavir was also recommended as a therapy for HCV genotype 1b. More recently, elbasvir (NS5A inhibitor)/grazoprevir (NS3/4A protease inhibitor) was also recommended as a potent therapy for HCV genotype 1b infection. This agent achieved an SVR12 as high as 96...
September 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29427481/treatment-of-hepatitis-c-results-in-real-life
#4
REVIEW
Christophe Hézode
Direct-acting antivirals (DAAs) have transformed traditional treatment options for hepatitis C virus (HCV) infection. DAA combinations have been shown to be highly effective in reducing the burden of chronic HCV infection in clinical trials and have been recommended by the European Association for the Study of the Liver (EASL) treatment guidelines. This review examines the results of second-generation DAA combinations in real-life clinical practice in patients with genotypes 1-3 and in those co-infected with HIV (real-world data in genotypes 4-6 are rare)...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29397016/risk-of-hbv-reactivation-in-hbv-hcv-coinfected-patients-with-compensated-liver-cirrhosis-treated-with-ombitasvir-paritaprevir-r-dasabuvir-ribavirin
#5
Carmen Monica Preda, Corneliu Petru Popescu, Cristian Baicus, Ileana Constantinescu, Alexandru Oproiu, Theodor Voiosu, Mircea Diculescu, Lucian Negreanu, Liana Gheorghe, Ioan Sporea, Anca Trifan, Emanoil Ceausu, Doina Proca, Mircea Manuc
Hepatitis B virus may reactivate in patients with chronic hepatitis C treated with direct acting antivirals. The aim of the present study was to investigate the risk of HBV reactivation in HBV+HCV coinfected patients with compensated liver cirhosis treated with Paritaprevir/Ombitasvir/Ritonavir, Dasabuvir with Ribavirin. We reviewed prospectively gathered data from a national cohort of 2070 patients with hepatitis C virus compensated liver cirrhosis who received reimbursed Paritaprevir/ Ombitasvir /r, Dasabuvir with Ribavirin for 12 weeks from the Romanian National Health Agency during 2015-2016...
February 3, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29396744/economic-evaluation-of-direct-acting-antivirals-for-hepatitis-c-in-norway
#6
Torbjørn Wisløff, Richard White, Olav Dalgard, Ellen J Amundsen, Hinta Meijerink, Astrid Louise Løvlie, Hilde Kløvstad
PURPOSE: New direct-acting antiviral (DAA) drugs have revolutionized the treatment of hepatitis C in recent years. OBJECTIVE: Our objective was to analyse the cost effectiveness of combinations of different DAAs compared with ribavirin and peginterferon-α-2a, taking into account rebates from tender negotiations. METHODS: We used a compartmental model specifically developed for Norway to simulate hepatitis C and complications with and without different DAAs...
February 2, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29390377/efficacy-and-safety-of-paritaprevir-ritonavir-ombitasvir-and-dasabuvir-with-ribavirin-for-the-treatment-of-hcv-genotype-1b-compensated-cirrhosis-in-patients-aged-70-years-or-older
#7
Anca Trifan, Carol Stanciu, Liana Gheorghe, Speranta Iacob, Manuela Curescu, Cristina Cijevschi Prelipcean, Gabriela Stefanescu, Irina Girleanu, Stefan Chiriac, Catalina Mihai, Ciprian Brisc, Adrian Goldis, Ioan Sporea, Egidia Miftode, Simona Bataga, Ion Rogoveanu, Carmen Preda, Florin Alexandru Caruntu, Ana-Maria Singeap
Advanced age has been a major limitation of interferon-based treatment for chronic hepatitis C virus (HCV) infection because of its poor response and tolerability. Direct-acting antiviral (DAA) drug regimens are safe and highly effective, allowing administration of treatment also in elderly. This study aims to assess the efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with ribavirin for the treatment of patients aged ≥70 years with HCV genotype 1b compensated cirrhosis.A total of 1008 patients with HCV genotype 1b compensated cirrhosis were prospectively treated with PrOD + ribavirin for 12 weeks, between December 2015 and July 2016...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29377566/ribavirin-dose-management-in-hcv-patients-receiving-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-with-ribavirin
#8
Jordan J Feld, David E Bernstein, Ziad Younes, Hans Van Vlierberghe, Lois Larsen, Fernando Tatsch, Peter Ferenci
BACKGROUND & AIMS: Some individuals with hepatitis C virus infection treated with direct-acting antivirals require ribavirin to maximize sustained virologic response rates. We describe the clinical management of ribavirin dosing in hepatitis C virus-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. METHODS: We performed a post hoc analysis of patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 12 or 24 weeks in six phase 3 trials...
January 27, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29377515/impact-of-interferon-free-regimens-on-the-glomerular-filtration-rate-during-treatment-of-chronic-hepatitis-c-in-a-real-life-cohort
#9
María Jesús Alvarez-Ossorio, Rui Sarmento E Castro, Rafael Granados, Juan Macías, Luis E Morano-Amado, María J Ríos, Dolores Merino, Enrique Nuño Álvarez, Antonio Collado, Montserrat Pérez-Pérez, Francisco Téllez, José María Martín, Josefina Méndez, Juan A Pineda, Karin Neukam
Little data is available on renal toxicity exerted by direct-acting antivirals (DAAs) in real-life. The aim of this study was to assess the impact of direct-acting antivirals against hepatitis C virus infection currently used in Spain and Portugal on the estimated glomerular filtration rate (eGFR) in clinical practise. From an international, prospective multicohort study, patients treated with DAAs for at least 12 weeks and with eGFR ≥30 ml/min/1.73 m2 at baseline were selected. eGFR was determined using the CKD-EPI formula...
January 28, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29377274/all-oral-daa-therapy-against-hcv-in-hiv-hcv-coinfected-subjects-in-real-world-practice-madrid-core-findings
#10
Juan Berenguer, Ángela Gil-Martin, Inmaculada Jarrin, Ana Moreno, Lourdes Dominguez, Marisa Montes, Teresa Aldámiz-Echevarría, María J Téllez, Ignacio Santos, Laura Benitez, José Sanz, Pablo Ryan, Gabriel Gaspar, Beatriz Alvarez, Juan E Losa, Rafael Torres-Perea, Carlos Barros, Juan V San Martin, Sari Arponen, María Teresa de Guzmán, Raquel Monsalvo, Ana Vegas, María T Garcia-Benayas, Regino Serrano, Luis Gotuzzo, María Antonia Menendez, Luis M Belda, Eduardo Malmierca, María J Calvo, Encarnación Cruz-Martos, Juan J González-García
We evaluated treatment outcomes in a prospective registry of HIV/HCV-coinfected patients treated with interferon-free direct-acting antiviral agent (DAA)-based therapy in hospitals from the region of Madrid between November 2014 and August 2016. We assessed sustained viral response (SVR) at 12 weeks after completion of treatment and used multivariable logistic regression to identify predictors of treatment failure. We evaluated 2,369 patients, of whom 59.5% were non-cirrhotic (Non-C), 33.9% had compensated cirrhosis (Co-C), and 6...
January 29, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29325996/direct-acting-antiviral-therapy-for-hepatitis-c-virus-infection-in-the-kidney-transplant-recipient
#11
REVIEW
Donald F Chute, Raymond T Chung, Meghan E Sise
Hepatitis C virus infection (HCV) is a common comorbidity in patients who have undergone kidney transplantation and is associated with increased morbidity and mortality compared with recipients who do not have chronic HCV infection. Because interferon-α-based therapies can precipitate acute rejection, they are relatively contraindicated after kidney transplantation. Thus, the majority of kidney transplant recipients with HCV remain untreated. There are now all-oral, interferon-free direct-acting antiviral therapies for HCV infection that are extremely effective and well tolerated in the general population...
January 9, 2018: Kidney International
https://www.readbyqxmd.com/read/29325476/twelve-weeks-of-ombitasvir-paritaprevir-r-and-dasabuvir-without-ribavirin-is-effective-and-safe-in-the-treatment-of-patients-with-hcv-genotype-1b-infection-and-compensated-cirrhosis-results-from-a-real-world-cohort-study
#12
Esther Chamorro-de-Vega, Alvaro Gimenez-Manzorro, Carmen-Guadalupe Rodriguez-Gonzalez, Vicente Escudero-Vilaplana, Ana De Lorenzo-Pinto, Irene Iglesias-Peinado, Ana Herranz-Alonso, Maria Sanjurjo Saez
OBJECTIVE: To explore the effectiveness and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV) for 12 weeks without ribavirin in adults with chronic HCV genotype 1b infection and compensated cirrhosis. METHODS: Observational study of a prospective cohort of adult patients with HCV genotype 1b infection and compensated cirrhosis who received 12 weeks of OBV/PTV/r and DSV without ribavirin. Effectiveness was assessed by recording the percentage of patients achieving sustained virological response at week 12 post-treatment (SVR12)...
January 11, 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29316062/efficacy-and-safety-of-ombitasvir-paritaprevir-ritonavir-combination-therapy-for-genotype-1b-chronic-hepatitis-c-patients-complicated-with-chronic-kidney-disease
#13
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Tadashi Ikegami, Noritomo Shimada, Keizo Kato, Hiroshi Abe, Tomomi Okubo, Norio Itokawa, Chisa Kondo, Shigeru Mikami, Toru Asano, Yoshimichi Chuganji, Yasushi Matsuzaki, Hidenori Toyoda, Takashi Kumada, Etsuko Iio, Yasuhito Tanaka, Katsuhiko Iwakiri
AIM: The aim of this study was to clarify the effects and safety of ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) therapy in genotype 1b chronic hepatitis C patients with non-dialysis chronic kidney disease (CKD). METHODS: This retrospective, multicenter study of 12-week OBT/PTV/r therapy included genotype 1b patients with non-dialysis CKD. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 . Virologic responses and treatment-emergent adverse events (TEAEs) in patients with CKD were compared with those in patients without CKD...
January 9, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29316039/treatment-of-hcv-infection-in-poland-at-the-beginning-of-the-interferon-free-era-the-epiter-2-study
#14
Robert Flisiak, Dorota Zarębska-Michaluk, Ewa Janczewska, Agnieszka Staniaszek, Andrzej Gietka, Włodzimierz Mazur, Magdalena Tudrujek, Krzysztof Tomasiewicz, Teresa Belica-Wdowik, Barbara Baka-Ćwierz, Dorota Dybowska, Waldemar Halota, Beata Lorenc, Marek Sitko, Aleksander Garlicki, Hanna Berak, Andrzej Horban, Iwona Orłowska, Krzysztof Simon, Łukasz Socha, Marta Wawrzynowicz-Syczewska, Jerzy Jaroszewicz, Zbigniew Deroń, Agnieszka Czauż-Andrzejuk, Jolanta Citko, Rafał Krygier, Anna Piekarska, Łukasz Laurans, Witold Dobracki, Jolanta Białkowska, Olga Tronina, Małgorzata Pawłowska
The aim of the EpiTer-2 study was to analyze patient characteristics and their medication for HCV infection in Poland at the beginning of the interferon-free era. Analysis of data of HCV infected patients treated during the initial period of availability of interferon-free regimens in Poland, who started therapy after 1 July 2015 and had available an efficacy evaluation report before 30 June 2017 was undertaken. A total of 2879 patients with chronic hepatitis C were entered, including 46% with liver cirrhosis...
January 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29314597/effect-of-ombitasvir-paritaprevir-ritonavir-dasabuvir%C3%A2-regimen-on-health-related-quality-of-life-for-patients-with-hepatitis-c
#15
Sammy Saab, Darshan Mehta, Stacie Hudgens, Nathan Grunow, Yanjun Bao, Brett Pinsky
BACKGROUND AND AIMS: This study analyzes health related quality of life (HRQoL) data from 8 randomized clinical trials using ombitasvir/paritaprevir/ritonavir and dasabuvir (3D) ± ribavirin [RBV] to investigate: [1] the impact of the treatment vs. placebo during treatment on HRQoL; [2] the sustainability of such treatment effect after 12-week treatment period; and [3] if results from [1] and [2] differ in subgenotypes 1a vs. 1b. METHODS: Six registration trials and 2 post-approval trials were pooled and analyzed using longitudinal mixed models (MM) to estimate the effect of 3D + RBV on HRQoL outcomes adjusting for baseline scores, as well as patient demographics and clinical characteristics...
January 5, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29288514/high-efficacy-of-ombitasvir-paritaprevir-ritonavir-plus-dasabuvir-in-hepatitis-c-genotypes-4-and-1-infected-patients-with-severe-chronic-kidney-disease
#16
Faisal M Sanai, Abdullah S Alghamdi, Ahmad A Afghani, Khalid Alswat, Adnan AlZanbagi, Mosfer N Alghamdi, Abdallah AlMousa, Mohammed Aseeri, Abdullah M Assiri, Mohamed A Babatin
Limited data has shown high efficacy of co-formulated ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in the treatment of hepatitis C virus (HCV) genotype (GT)-4, and combined with dasabuvir (DSV) in GT1 patients, with chronic kidney disease (CKD) stage 4-5 (<30 mL/min/1.73 m2 ). We assessed real-world safety and efficacy of OBV/PTV/r ± DSV in GT1 and 4-infected patients. METHODS: In this observational cohort (n=67), we enrolled stage 4-5 CKD treatment-naïve or Peginterferon/RBV-experienced GT4-infected patients (n=32) treated for 12-24 weeks with OBV/PTV/r ± RBV, and plus DSV in GT1 patients (n=35, including 3 with GT1/4 co-infection)...
December 29, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29279486/differences-in-the-serum-4%C3%AE-hydroxycholesterol-levels-of-patients-with-chronic-hcv-infection-a-possible-impact-on-the-efficacy-and-safety-of-ifn-free-treatment
#17
Takeshi Hirayama, Tadashi Ikegami, Akira Honda, Teruo Miyazaki, Sho-Ichiro Yara, Motoyuki Kohjima, Makoto Nakamuta, Yasushi Matsuzaki
Since the majority of direct-acting antivirals (DAAs) that are used in the treatment of HCV infection are mainly metabolized by CYP3A4, it is hypothesized that inter-individual differences in CYP3A4 activity may be associated with the bioavailability of these agents. Methods The level of serum 4β-hydroxycholesterol (4βHC), a surrogate marker of CYP3A4 activity, was determined by LC-MS/MS in samples obtained from patients with HCV infection (CHCs) as well as healthy control subjects (CTLs). Serum samples obtained from patients treated with either asunaprevir/daclatasvir (ASV/DCV) or ombitasvir/paritaprevir/ritonavir (OTV/PTV/r) were used for additional assays...
December 27, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29228392/hepatic-pharmacokinetics-and-pharmacodynamics-with-ombitasvir-paritaprevir-ritonavir-plus-dasabuvir-treatment-and-variable-ribavirin-dosage
#18
Andrew H Talal, Emily O Dumas, Barbara Bauer, Richard M Rejman, Andrew Ocque, Gene D Morse, Danijela Lucic, Gavin A Cloherty, Jennifer King, Jiuhong Zha, Hongtao Zhang, Daniel E Cohen, Nancy Shulman, Jean-Michel Pawlotsky, Christophe Hézode
Background: It is unknown whether ribavirin (RBV) co-administration modifies the early rate of decline of hepatitis C virus (HCV) RNA in the liver versus plasma compartments, specifically. Methods: This partially randomized, open-label, phase 2 study enrolled treatment-naïve, non-cirrhotic patients with HCV genotype (GT) 1a. Patients were randomized 1:1 into Arms A and B, and then enrolled in Arm C. Patients received ombitasvir/paritaprevir/ritonavir + dasabuvir for 12 weeks with either: no RBV for the first 2 weeks followed by weight-based dosing thereafter (Arm A), weight-based RBV for all 12 weeks (Arm B), or low-dose RBV (600 mg) once daily for all 12 weeks...
September 27, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29210779/remarkable-plasma-hiv-rna-decrease-by-ombitasvir-paritaprevir-ritonavir-in-an-hiv-hcv-coinfection-case
#19
Yukihiro Yoshimura, Nobuyuki Miyata, Hirokazu Komatsu, Natsuo Tachikawa
No abstract text is available yet for this article.
January 2, 2018: AIDS
https://www.readbyqxmd.com/read/29194858/low-incidence-of-hepatitis-b-virus-reactivation-and-subsequent-hepatitis-in-patients-with-chronic-hepatitis-c-receiving-direct-acting-antiviral-therapy
#20
Akihiro Tamori, Seigo Abiru, Hirayuki Enomoto, Kiyohide Kioka, Masaaki Korenaga, Joji Tani, Masaru Enomoto, Masaya Sugiyama, Tsutomu Masaki, Norifumi Kawada, Hiroshi Yatsuhashi, Shuhei Nishiguchi, Masashi Mizokami
To determine the clinical characteristics of hepatitis B virus (HBV) reactivation in patients undergoing interferon-free anti-hepatitis C virus (HCV) therapy, we examined HBV DNA in 25 HBV co-infected patients and 765 patients with resolved HBV infection during and after treatment with direct-acting antiviral agents (DAAs). Among those with HCV genotype 1, asunaprevir plus daclatasvir was administered to 160 patients, sofosbuvir (SOF) plus ledipasvir to 438 patients, and paritaprevir plus ombitasvir and ritonavir to 25 patients...
November 30, 2017: Journal of Viral Hepatitis
keyword
keyword
59050
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"